Basit öğe kaydını göster

dc.contributor.authorÇakıcı, Çağrı
dc.contributor.authorDaylan, Benay
dc.contributor.authorAyla, Şule
dc.contributor.authorYiğit, Pakize
dc.contributor.authorYavuz Dokgöz, Elif
dc.contributor.authorYigitbaşı, Türkan
dc.date.accessioned2022-05-27T07:34:06Z
dc.date.available2022-05-27T07:34:06Z
dc.date.issued2022en_US
dc.identifier.citationÇakıcı, Ç., Daylan, B., Ayla, Ş., Yiğit, P., Yavuz Dokgöz, E. ve Yigitbaşı, T. (2022). Can lactate dehydrogenase inhibition be increased efficiency of 1,25(OH)2 D3 vitamin in prostate cancer animal model? FASEB Journal : Official publication of the Federation of American Societies for Experimental Biology, 36. https://doi.org/10.1096/fasebj.2022.36.S1.R2370en_US
dc.identifier.issn1530-6860
dc.identifier.urihttps://doi.org/10.1096/fasebj.2022.36.S1.R2370
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9466
dc.description.abstractThe Warburg effect explains that the cancer cell's metabolism is programmed based on anaerobic glycolysis to support the proliferation and anabolic growth of cancer cells. LDH-A is the form of LDH found in cancer cells, which is the main regulator of anaerobic glycolysis. Increased LDH-A activity; promotes tumor growth and metastasis, increases migration and invasion. The active form of vitamin D (1,25(OH)2 D3 ), can have a protective effect against cancer by acting on apoptosis induction, stimulation of cell differentiation, anti-inflammatory, anti-proliferative effect, angiogenesis, and invasion through different mechanisms. We hypothesis that reprogramming cancer cell's glucose metabolism to oxidative phosphorylation with LDH-A inhibitor will increase the effectiveness of 1,25(OH)2 D3 vitamin in prostate cancer (PCa). For this purpose, 50 male C57BL/6 mice and Tramp-C2 PCa cell lines were used to develop PCa model (1- Control group; 2- PCa control group; 3- 1,25(OH)2 D3 vitamin group (5 µg/kg 1,25(OH)2 D3 vitamin); 4- LDH-A inhibitor (300 mg/kg sodium oxamate) group; 5- Combined group (LDH-A inhibitor + 1,25(OH)2 D3 ). CK18-M30, lactate and oxidative stress values were calculated from serum samples. TUNEL staining for apoptosis analysis, western blot analysis for epithelial to mesenchymal transition (EMT) to evaluate metastasis were performed from tumor tissue samples. Hematoxylin-eosin staining (HE) was performed in the liver and periodic acid schiff staining (PAS) was performed in the kidney tissues to evaluate toxicity. When the serum lactate levels were examined, it was shown that the LDH-A inhibitor reversed the Warburg effect. 1,25(OH)2 D3 , LDH-A inhibitor, and LDH-A inhibitor + 1,25(OH)2 D3 treatment groups significantly increased oxidative stress and apoptosis (p<0.05). Moreover, 1,25(OH)2 D3 treatment group had more toxic effect on the kidney. However, when the two treatments groups were combined, the toxicity of vitamin D was significantly decreased (p[removed]0.05). When the effect on EMT was examined, it was observed that the 1,25(OH)2 D3 , LDH-A inhibitor increased the expression of E-cadherin and decreased the expression of N-cadherin (p[removed]0.05). Our results suggest that LDH-A inhibitor + 1,25(OH)2 D3 combined treatment group increased apoptosis, oxidative stress, and decreased toxic effect of 1,25(OH)2 D3 in the kidney. So, tumor volume was decreased and the effectiveness of 1,25(OH)2 D3 vitamin was increased. For metastasis, E-cadherin was increased, and N-cadherin was decreased in the LDH-A inhibitor and 1,25(OH)2 D3 vitamin group. However, the transcription factors results were contradictory. For this reason, EMT results needed to be further research to understand the mechanism. Taken together, our current data indicate that LDH-A inhibitor reprogrammed glucose metabolism and increased effectiveness of 1,25(OH)2 D3 vitamin in PCa animal model.en_US
dc.language.isoengen_US
dc.publisherNLM (Medline)en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject1,25(OH)2D3en_US
dc.subjectLDH-A Inhibitoren_US
dc.subjectWarburg Effecten_US
dc.titleCan lactate dehydrogenase inhibition be increased efficiency of 1,25(OH)2 D3 vitamin in prostate cancer animal model?en_US
dc.typearticleen_US
dc.relation.ispartofFASEB Journal : Official publication of the Federation of American Societies for Experimental Biologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyokimya Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Histoloji ve Embriyoloji Ana Bilim Dalıen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Biyoistatistik ve Tıp Bilişimi Ana Bilim Dalıen_US
dc.authorid0000-0002-8662-5284en_US
dc.authorid0000-0002-8302-1127en_US
dc.authorid0000-0003-2143-5268en_US
dc.authorid0000-0002-5919-1986en_US
dc.authorid0000-0002-0675-1839en_US
dc.identifier.volume36en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1096/fasebj.2022.36.S1.R2370en_US
dc.institutionauthorÇakıcı, Çağrı
dc.institutionauthorDaylan, Benay
dc.institutionauthorAyla, Şule
dc.institutionauthorYiğit, Pakize
dc.institutionauthorYigitbaşı, Türkan
dc.identifier.scopus2-s2.0-85130072409en_US
dc.identifier.scopusqualityQ1en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster